|
|
Blood, 1 March 2007, Vol. 109, No. 5, pp. 2243-2249.
Prepublished online as a Blood First Edition Paper on October 26, 2006; DOI 10.1182/blood-2006-08-042820.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells
Abdulbaqi Al-toma1,
Otto J. Visser2,
Hyacintha M. van Roessel2,
B. Mary E. von Blomberg3,
Wieke H. M. Verbeek1,
Petra E. T. Scholten3,
Gert J. Ossenkoppele2,
Peter C. Huijgens2, and
Chris J. J. Mulder1
Departments of1 Gastroenterology,
2 Hematology, and
3 Clinical Pathology, VU University Medical Center, Amsterdam, The Netherlands
Autologous hematopoietic stem cell transplantation (ASCT) is an increasingly accepted treatment for refractory autoimmune diseases. Refractory celiac disease with aberrant T cells (RCD type II) is unresponsive to available therapies and carries a high risk of transition into enteropathy associated T-cell lymphoma (EATL). This study reports on the feasibility, safety, and efficacy of ASCT in patients with RCD type II. Thirteen patients with RCD type II were evaluated. Seven patients (4 men, 3 women, mean age 61.5 years [range, 51-69 years]) underwent transplantation. After conditioning with fludarabine and melphalan, ASCT was performed. Patients were monitored for response, adverse effects, and hematopoietic reconstitution. All 7 patients completed the mobilization and leukapheresis procedures successfully and subsequently underwent conditioning and transplantation. Engraftment occurred in all patients. No major nonhematologic toxicity or transplantation-related mortality was observed. There was a significant reduction in the aberrant T cells in duodenal biopsies associated with improvement in clinical well-being and normalization of hematologic and biochemical markers (mean follow-up, 15.5 months; range, 7-30 months). One patient died 8 months after transplantation from progressive neuroceliac disease. These preliminary results showed that high-dose chemotherapy followed by ASCT seems feasible and safe and might result in long-term improvement of patients with RCD type II whose condition did not respond promptly to available drugs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
JAMA,
February 27, 2008;
299(8):
925 - 936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Barton and J. A. Murray
Commentary
Clin. Chem.,
February 1, 2008;
54(2):
445 - 445.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Cassinotti, C Annaloro, S Ardizzone, F Onida, A D. Volpe, M Clerici, P Usardi, S Greco, G Maconi, G B. Porro, et al.
Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease
Gut,
February 1, 2008;
57(2):
211 - 217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H.R. Green and C. Cellier
Celiac Disease
N. Engl. J. Med.,
October 25, 2007;
357(17):
1731 - 1743.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Al-toma, W H M Verbeek, M Hadithi, B M E von Blomberg, and C J J Mulder
Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience
Gut,
October 1, 2007;
56(10):
1373 - 1378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Kline, S. M.L. Neudorf, and H. I. Baron
Correction of Celiac Disease After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Pediatrics,
October 1, 2007;
120(4):
e1120 - e1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
